Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 6/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 4/20 | 0.43 |
| ▸ | SENP1 | Q9P0U3 | 1/20 | 0.42 |
| ▸ | TACR2 | P21452 | 1/20 | 0.42 |
| ▸ | CTSL | P07711 | 2/20 | 0.41 |
| ▸ | CTSB | P07858 | 2/20 | 0.41 |
| ▸ | PREP | P48147 | 2/20 | 0.40 |
| ▸ | CASP1 | P29466 | 1/20 | 0.40 |
| ▸ | NAAA | Q02083 | 1/20 | 0.40 |
| ▸ | CTSK | P43235 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13197153 | 0.91 | HDAC6 (0.42) | HDAC6HDAC1HDAC8TACR2CTSL | |
| SCHEMBL13197152 | 0.88 | HDAC6 (0.44) | HDAC6HDAC1HDAC8TACR2CTSL | |
| SCHEMBL12946468 | 0.84 | CASP1 (0.43) | HDAC6HDAC1HDAC8TACR2CTSL | |
| SCHEMBL949976 | 0.82 | CASP1 (0.53) | HDAC6HDAC1HDAC8TACR2CTSL | |
| SCHEMBL12914629 | 0.82 | CASP1 (0.53) | HDAC6HDAC1HDAC8TACR2CTSL | |
| SCHEMBL14370035 | 0.82 | CASP1 (0.53) | HDAC6HDAC1HDAC8TACR2CTSL | |
| SCHEMBL12450524 | 0.81 | CASP1 (0.46) | HDAC6HDAC1HDAC8TACR2CTSL | |
| SCHEMBL12914630 | 0.76 | HDAC6 (0.43) | HDAC6HDAC1HDAC8PREP | |
| SCHEMBL8189734 | 0.73 | CASP3 (0.52) | CTSLCTSBPREPCASP1NAAA | |
| SCHEMBL8189732 | 0.73 | CASP3 (0.52) | CTSLCTSBPREPCASP1NAAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7772366-B2 | Inhibitors of interleukin-1β converting enzyme | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-08-10 | — | — | US | disclosed |
| US-20080070953-A1 | Inhibitors of interleukin-1 beta converting enzyme | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-03-20 | — | — | US | disclosed |
| US-7288624-B2 | Inhibitors of interleukin-1β converting enzyme | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070953-A1 | Inhibitors of interleukin-1 beta converting enzyme | IL1B, IL1A, IL1R1 | HDAC6 1443/4885HDAC1 717/4885HDAC8 1891/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.